Non-profit drug research and development: the case study of Genethon
Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2018.1545514 |
| _version_ | 1797230543024160768 |
|---|---|
| author | Szymon Jarosławski Mondher Toumi |
| author_facet | Szymon Jarosławski Mondher Toumi |
| author_sort | Szymon Jarosławski |
| collection | DOAJ |
| description | Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms. Like other non-profits, Genethon is willing to adopt an ethical attitude toward their donors by pricing their products affordably. It remains to be seen if the approach to internalize the marketing authorization, manufacturing and distribution activities prove to be efficient and sustainable. Also, the firm faces an ethical dilemma because lower prices of innovative drugs can dry the for-profit R&D in the area and prevent patient access to future innovations. |
| first_indexed | 2024-04-24T15:30:09Z |
| format | Article |
| id | doaj.art-a33ecda8b71c4bdc9aa0669033ba8fb2 |
| institution | Directory Open Access Journal |
| issn | 2001-6689 |
| language | English |
| last_indexed | 2024-04-24T15:30:09Z |
| publishDate | 2019-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj.art-a33ecda8b71c4bdc9aa0669033ba8fb22024-04-02T04:51:31ZengMDPI AGJournal of Market Access & Health Policy2001-66892019-01-017110.1080/20016689.2018.15455141545514Non-profit drug research and development: the case study of GenethonSzymon Jarosławski0Mondher Toumi1Aix-Marseille UniversityAix-Marseille UniversityNon-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms. Like other non-profits, Genethon is willing to adopt an ethical attitude toward their donors by pricing their products affordably. It remains to be seen if the approach to internalize the marketing authorization, manufacturing and distribution activities prove to be efficient and sustainable. Also, the firm faces an ethical dilemma because lower prices of innovative drugs can dry the for-profit R&D in the area and prevent patient access to future innovations.http://dx.doi.org/10.1080/20016689.2018.1545514non-profitresearch and developmentpharmaceutical industryorphan drugspricingethics |
| spellingShingle | Szymon Jarosławski Mondher Toumi Non-profit drug research and development: the case study of Genethon Journal of Market Access & Health Policy non-profit research and development pharmaceutical industry orphan drugs pricing ethics |
| title | Non-profit drug research and development: the case study of Genethon |
| title_full | Non-profit drug research and development: the case study of Genethon |
| title_fullStr | Non-profit drug research and development: the case study of Genethon |
| title_full_unstemmed | Non-profit drug research and development: the case study of Genethon |
| title_short | Non-profit drug research and development: the case study of Genethon |
| title_sort | non profit drug research and development the case study of genethon |
| topic | non-profit research and development pharmaceutical industry orphan drugs pricing ethics |
| url | http://dx.doi.org/10.1080/20016689.2018.1545514 |
| work_keys_str_mv | AT szymonjarosławski nonprofitdrugresearchanddevelopmentthecasestudyofgenethon AT mondhertoumi nonprofitdrugresearchanddevelopmentthecasestudyofgenethon |